Agammaglobulinemia
Return to Library
|
Free Agammaglobulinemia Articles |
|
|
|
|
Scientists at University of Tehran publish research in immunodeficiency
2009 JUN 15 - (NewsRx.com) -- "Intravenous immunoglobulin (IVIG) replacement therapy improves health-related quality of life in patients with a primary immunodeficiency disease, although there have been reports of adverse reactions associated with its regular administration. The study population was composed of 99 patients with primary antibody deficiencies," scientists writing in the Journal of Investigational Allergology and Clinical Immunology report. "All the patients were diagnosed with a primary immunodeficiency disease and received at least 4 infusions of IVIG at the Children's Medical Center Hospital, Tehran, Iran over a 13-year period (1995-2007). A total of 3004 infusions were recorded, and 216 (7.2%) of these were associated with adverse reactions in 66 patients, Adverse reactions were classified as mild (172 reactions), moderate (41 reactions), and severe (3 reactions). The rate of adverse reaction varied by diagnosis from 3.35% in patients with X-linked agammaglobulinemia to 17.4% in IgG subclass deficiency. There were no age-related differences in the rates of adverse reactions," wrote S. Dashtikhavidaki and colleagues, University of Tehran. The researchers concluded: "Adverse reactions to IVIG infusions are. occasionally encountered; therefore, physicians and nurses should be aware of these reactions in order to manage and prevent them." Dashtikhavidaki and colleagues published their study in the Journal of Investigational Allergology and Clinical Immunology (Adverse Reactions of Prophylactic Intravenous Immunoglobulin; A 13-Year Experience With 3004 Infusions in Iranian Patients With Primary Immunodeficiency Diseases. Journal of Investigational Allergology and Clinical Immunology, 2009;19(2):139-145). Additional information can be obtained by contacting A. Aghamohammadi, University of Tehran Med Science, Children's Med Center Hospital, Dept. of Allergy & Clinic Immunology, 62 Qarib St., Keshavarz Blvd., POB 14185-863, Tehran 14194, Iran. The publisher of the Journal of Investigational Allergology and Clinical Immunology can be contacted at: Esmon Publicidad S a, Calle Balmes 209, 3 2, Barcelona, 08006, Spain. Keywords: Iran, Clinical Immunology, Immunodeficiency, Immunology, Intravenous Immunoglobulin, Quality of Life, Therapy, Treatment, University of Tehran. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
